Up-regulation of ABCG1 is associated with methotrexate resistance in acute lymphoblastic leukemia cells

Front Pharmacol. 2024 Jan 8:14:1331687. doi: 10.3389/fphar.2023.1331687. eCollection 2023.

Abstract

Acute lymphoblastic leukemia (ALL) is a prevalent hematologic malignancy in children, and methotrexate (MTX) is a widely employed curative treatment. Despite its common use, clinical resistance to MTX is frequently encountered. In this study, an MTX-resistant cell line (Reh-MTXR) was established through a stepwise selection process from the ALL cell line Reh. Comparative analysis revealed that Reh-MTXR cells exhibited resistance to MTX in contrast to the parental Reh cells. RNA-seq analysis identified an upregulation of ATP-binding cassette transporter G1 (ABCG1) in Reh-MTXR cells. Knockdown of ABCG1 in Reh-MTXR cells reversed the MTX-resistant phenotype, while overexpression of ABCG1 in Reh cells conferred resistance to MTX. Mechanistically, the heightened expression of ABCG1 accelerated MTX efflux, leading to a reduced accumulation of MTX polyglutamated metabolites. Notably, the ABCG1 inhibitor benzamil effectively sensitized Reh-MTXR cells to MTX treatment. Moreover, the observed upregulation of ABCG1 in Reh-MTXR cells was not induced by alterations in DNA methylation or histone acetylation. This study provides insight into the mechanistic basis of MTX resistance in ALL and also suggests a potential therapeutic approach for MTX-resistant ALL in the future.

Keywords: ABCG1; ALL; MTX resistance; chemosensitivity; epigenetic modification.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the National Natural Science Foundation of China (82070159 to HL, 81970141 to B-BZ), the Science and Technology Commission of Pudong New Area Foundation (PKJ2020-Y05 to YC, PKJ2023-Y45 to HL), National Key Research and Development Program of China (No. 2021YFA1100800 to B-BZ), Natural Science Foundation of Shanghai (22ZR1440000 to HL, 22ZR1439900 to B-BZ), Shanghai Key Laboratory of Clinical Molecular Diagnostics for Pediatrics (20DZ2260900 to B-BZ), Natural Science Foundation of Fujian Province (2023J01184 to HL).